Summary
Conclusions: Activation of the immune system in pancreatic cancer is demonstrated by increased serum levels of neopterin, soluble Interleukin 2 receptor (sIL-2R), and Interleukin 6 (IL-6). Determination of these parameters does not provide benefit in the diagnosis of pancreatic cancer.
Background: The aim of the study was to define the diagnostic value of serum neopterin, an in vivo marker of macrophage activity, in pancreatic cancer.
Methods: Thirty-four patients with pancreatic cancer were studied. According to the UICC TNM classification 6 were in stage I, 9 in stage II, 6 in stage III, and 13 in stage IV. Twenty-four patients with chronic pancreatitis, 72 healthy blood donors, and 20 patients with jaundice resulting from gallstones were used as control groups. Neopterin, tumor necrosis factor (TNF), sIL-2R, and IL-6 were measured in serum in the different groups; Ca 19-9 was also measured in cancer and pancreatitis.
Results: Serum levels of neopterin, sIL-2R, and IL-6 were higher in cancer than in pancreatitis and healthy donors, and in pancreatitis higher than in donors. Serum TNF was similar in the three groups. Serum levels of neopterin, TNF, sIL-2R, and IL-6 were not related to the tumor stage or to Ca 19-9 levels. A positive correlation was found between sIL-2R and neopterin levels. Neopterin levels in obstructive jaundice were similar to those of pancreatitis. Ca 19-9 at the recommended cutoff of 37 U/mL showed the best sensitivity and specificity (88.2 and 87.5%, respectively). At the selected cutoff neopterin, TNF, sIL-2R, and IL-6 showed low sensitivity and specificity in differentiating cancer from pancreatitis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987; 60: 2284–2303.
Müller MM, Curtius HC, Herold M, Hüber CH. Neopterin in clinical practice. Clin Chim Acta 1991; 201: 1–16.
Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as a marker for activation of cellular immunity: immunological basis and clinical application. Adv Clin Chem 1989; 27: 81–141.
Wachter H, Fuchs D, Hausen A, Reibnegger G, Weiss G, Werner ER, et al. Neopterin: Biochemistry, Methods, Clinical Application. Walter de Gruyter, Berlin, 1992.
Vomo G, Spada O, Manes G, Feola B, Misso S, Cavallera A, Rabitti PG. Neopterin in acute pancreatitis. Scand J Gastroenterol 1996; 31: 1037–1039.
Reibnegger G, Fuchs D, Fuith LC, Hausen A, Werner-ER, Werner-Felmayer G, et al. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev 1991; 15: 483–489.
Hausen A, Fuchs D, Reibnegger G, Wener ER, Wachter H. Neopterin in clinical use. Pteridines 1989; 1: 3–10.
Haglund B, Roberts PJ, Kuusela P, Scheinin TM, Mäkelä O, Jalanko H. Evaluation of Ca 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 1986; 53: 197–202.
Werner ER, Werner-Felmayer G, Fuchs D, Hausen G, Reibnegger G, Wachter H. Tertrahydrobiopterin biosinthetic activation in human macrophages, fibroblasts, TPH-1 and T24 cells. J Biol Chem 1990; 265: 3188–3192.
Reibnegger GJ, Bichler AH, Dapunt O, Fuchs DN, Fuith LC, Hausen A, et al. Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res 1986; 46: 950–955.
Reibnegger G, Hetzel H, Fuchs D, Fuith LC, Hausen A, Werner ER, et al. Clinical significance of neopterin for prognosis and follow-up in ovarian cancer. Cancer Res 1987; 47: 4977–4981.
Lawenhaupt A, Ekman P, Engeoth P, Erikkson A, Nilsson B, Nordström L. Serum levels of neopterin as related to the prognosis of human prostatic carcinoma. Eur Urol 1986; 12: 422–425.
Kawasaki H, Watanabe H, Yamada S, Watanabe K, Suyama A. Prognostic significance of urinary neopterin levels in patients with hepatocellular carcinoma. Tohoku J Exp Med 1988; 155: 311–318.
Denz H, Grünewald K, Thaler J, Huber H, Fuchs D, Hausen A, et al. Urinary neopterin as a prognostic marker in haematological neoplasias. Pteridines 1989; 1: 167–170.
Lissoni P, Brivio F, Fumagalli L, Galimberti C, Cataldo M, Marsili MT, et al. A study of interactions among markers of macrophage function in metatstatic solid tumor: neopterin levels in relation to those of tumor necrosis-alpha and of soluble interleukin-2 receptors. J Biol Regul Homeost Agents 1994; 8: 32–35.
Schmielau J, Kalthoff H, Roeder C, Schmiegel W. Cytokines and the biology of pancreatic cancer, in Pancreatic Cancer—Molecular and Clinical Advances. Neoptolemos JP, Lemoine NR, eds. Blackwell Science 1996; pp. 36–50.
Zorn U, Dellmann I, Grosse J, Kirchner H, Paliwoda H, Atzpodien J. Soluble interleukin-2 receptors abrogate IL-2 induced activation of peripheral mononuclear cells. Cytokine 1994; 6: 358–364.
Pezzilli R, Billi P, Beltrandi E, Mancini R, Casadei-Maldini M, Casadei R, et al. Serum soluble interleukin-2 receptor in pancreatic cancer and chronic pancreatitis. Ital J Gastroenterol 1994; 26: 137–140.
Lissoni P, Barni S, Rovelli F, Viviani S, Maestroni GJ Conti A, et al. The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer 1990; 26: 33–36.
Falconer JS, Fearon KCH, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expediture in cachectic patients with pancreatic cancer. Ann Surg 1994; 219: 325–331.
Blay JK, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum levels of interleukin-6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317–3322.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Manes, G., Spada, O.A., Rabitti, P.G. et al. Neopterin serum levels in pancreatic adenocarcinoma. International Journal of Pancreatology 25, 31–37 (1999). https://doi.org/10.1385/IJGC:25:1:31
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/IJGC:25:1:31